Login to Your Account



Somaxon Gets up to $134M+ for Silenor Insomnia Deal

By Tom Wall


Thursday, June 9, 2011
Somaxon Pharmaceuticals Inc. investors may have slept better following the San Diego company's announcement that Paladin Labs Inc., of Montreal, will commercialize Silenor (doxepin) for the treatment of insomnia in Canada, South America and Africa.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription